Andra AP fonden Decreases Position in Agilent Technologies, Inc. $A

Andra AP fonden lowered its position in Agilent Technologies, Inc. (NYSE:A) by 7.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,300 shares of the medical research company’s stock after selling 7,600 shares during the quarter. Andra AP fonden’s holdings in Agilent Technologies were worth $11,836,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Generation Investment Management LLP increased its holdings in Agilent Technologies by 19.8% during the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock valued at $582,976,000 after acquiring an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after purchasing an additional 604,124 shares in the last quarter. Mackenzie Financial Corp grew its position in shares of Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after purchasing an additional 548,344 shares during the last quarter. Woodline Partners LP increased its stake in shares of Agilent Technologies by 681.6% during the 1st quarter. Woodline Partners LP now owns 522,073 shares of the medical research company’s stock worth $61,072,000 after purchasing an additional 455,276 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Agilent Technologies by 16.2% during the 2nd quarter. Nordea Investment Management AB now owns 3,213,748 shares of the medical research company’s stock worth $383,143,000 after purchasing an additional 447,207 shares in the last quarter. 87.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on A shares. Barclays upped their target price on Agilent Technologies from $125.00 to $150.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Robert W. Baird upped their price objective on Agilent Technologies from $141.00 to $142.00 and gave the company an “outperform” rating in a research report on Thursday, August 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Agilent Technologies in a research note on Wednesday, October 8th. UBS Group raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and boosted their target price for the company from $130.00 to $170.00 in a research note on Wednesday, October 8th. Finally, Rothschild & Co Redburn started coverage on shares of Agilent Technologies in a report on Wednesday, October 8th. They set a “buy” rating and a $165.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $149.62.

Agilent Technologies Stock Performance

NYSE:A opened at $147.71 on Friday. The company has a market cap of $41.87 billion, a P/E ratio of 34.67, a P/E/G ratio of 4.67 and a beta of 1.29. The firm’s 50 day moving average is $135.06 and its two-hundred day moving average is $121.97. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $153.84. The company has a quick ratio of 1.71, a current ratio of 2.25 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 22nd. Stockholders of record on Tuesday, September 30th were issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is 23.24%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.